ID   K562YO
AC   CVCL_0369
DR   MCCL; MCC:0000263
DR   Wikidata; Q54899422
RX   PubMed=7506674;
RX   PubMed=7534132;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 20
//
RX   PubMed=7506674;
RA   Ogawa K., Tashima M., Toi T., Sawai H., Sawada H., Fujita J.,
RA   Maruyama Y., Okuma M.;
RT   "Inhibition of erythroid differentiation by stem cell factor in K562
RT   cells expressing the c-kit gene.";
RL   Exp. Hematol. 22:45-51(1994).
//
RX   PubMed=7534132; DOI=10.1182/blood.V85.6.1496.bloodjournal8561496;
RA   Ogawa K., Takeda Y., Tashima M., Sawai H., Toi T., Okazaki T.,
RA   Sawada H., Maruyama Y., Okuma M.;
RT   "High expression of c-kit in K562YO cells due to the prolonged
RT   half-life of its mRNA: the effects of modification with
RT   serine/threonine kinase signals.";
RL   Blood 85:1496-1503(1995).
//